Research
New hope for treating pancreatic cancer: Targeting the ‘recycler’ protein USP25
An innovative new study may revolutionise pancreatic cancer therapy by targeting the ‘recycler’ protein USP25 to reduce the growth of cancer cells.
Our response to “gremlin therapy” research that suggests pancreatic cancer can be reversed
New research from the Institute of Cancer Research suggests that it could be possible to reverse a key process that enables pancreatic cancer cells to grow and spread in the body.
Our Research Involvement Network: Shaping the future of pancreatic cancer research
Dr Naureen Starling is a Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust specialising in the treatment of gastrointestinal cancers, as well as researching new therapies.
Our response to the mRNA pancreatic cancer vaccine trial
Our Head of Research, Dr Chris MacDonald comments on the exciting trial results presented at the American Society of Clinical Oncology conference in Chicago.
Pancreatic Cancer UK Discovery and Translational Research Forum, 13 & 14 June 2022
New research project: what is pancreatic exocrine insufficiency and how can we diagnose it more quickly?
Pancreatic exocrine insufficiency (PEI) occurs when the pancreas becomes unable to produce enough enzymes to break down food, and effectively causes the body to starve. The condition affects 60-90% of people with pancreatic cancer.
What’s the link between diabetes and pancreatic cancer?
Over 40% of people living with pancreatic cancer are diagnosed with diabetes. We don't know why or how this happens, but understanding this link between diabetes and pancreatic cancer could hold a vital key to earlier diagnosis.
Pancreatic Cancer UK Discovery and Translational Research Forum
Research Involvement Network opportunity: Join a Patient Advisory Panel and help update the Quality of Life questionnaire for pancreatic cancer
Introducing SABR treatment for pancreatic cancer
In Autumn 2020, Pancreatic Cancer UK helped to submit a proposal to NHS England, asking them to commission a type of radiotherapy called SABR (Stereotactic Ablative Body Radiotherapy), for people with locally advanced pancreatic cancer (LAPC). Now, SABR treatment has been commissioned for rollout in England, thanks to a group of healthcare professionals and Pancreatic Cancer UK's Research Involvement Network (RIN).
COVID Cancer Antibody Survey – Nurse Nicci and the NHS need your help
PCUK specialist nurse Nicci encourages people to take part in an NHS survey that wants to find out how well the COVID-19 vaccines work for people with cancer.
Meet Professor Michelle Garrett
We are delighted to announce that we have appointed Professor Michelle Garrett as the new Chair of Pancreatic Cancer UK’s Scientific Advisory Board (SAB). Michelle is Professor of Cancer Therapeutics in the School of Biosciences at the University of Kent